Testosterone Cypionate Injections — CPB 1014 | AETNA Coverage Update

Aetna modified CPB 1014 covering testosterone cypionate injections (J1071, J1072), effective December 20, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated its testosterone cypionate coverage policy under CPB 1014. This policy governs reimbursement for Azmiro and Depo-Testosterone (and their generics), billed under HCPCS codes J1071 and J1072. The updated policy includes medical necessity criteria for both hypogonadism and gender dysphoria indications and adds specific prescriber specialty requirements for adolescent gender dysphoria cases. If your practice bills testosterone cypionate injections to Aetna commercial plans, review your documentation workflows now — before December 20, 2025.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Testosterone Cypionate Injections
Policy Code	CPB 1014
Change Type	Modified
Effective Date	December 20, 2025
Impact Level	High
Specialties Affected	Endocrinology, Internal Medicine, Family Medicine, OB/GYN, Pediatric Endocrinology, Urology, Primary Care
Key Action	Audit documentation for all active testosterone cypionate patients against updated medical necessity criteria before December 20, 2025

---

Aetna Testosterone Cypionate Coverage Criteria and Medical Necessity Requirements 2025

The updated policy covers two indications: primary or hypogonadotropic hypogonadism and gender dysphoria. Everything else is off the table.

Hypogonadism (E29.1, E23.0)

For hypogonadism, Aetna requires at least two confirmed low morning testosterone levels before therapy starts. Both readings must fall below the reference laboratory range or below thresholds set by current practice guidelines. One low result is not enough. Document both draws, with dates and lab reference ranges, in the chart before you submit J1071 or J1072.

This requirement matters for claim denial risk. A single low morning testosterone result — even a dramatically low one — will not satisfy Aetna's medical necessity threshold under the updated policy.

For continuation of therapy, the bar is slightly lower: Aetna requires only one confirmed low morning testosterone level from before therapy started. But that prior-to-treatment result must be in the chart. If your team inherited a patient from another practice, get those original labs before billing continuation.

Gender Dysphoria — Adults (F64.0–F64.9)

For adult members with a gender dysphoria diagnosis, all five of the following must be met and documented:

Every one of these is a documentation requirement, not just a clinical checkbox. Missing any single element creates exposure for claim denial.

Gender Dysphoria — Adolescents

Adolescent cases carry one additional criterion: the member must have reached Tanner stage 2 of puberty or greater. The policy also includes a prescriber specialty requirement worth noting. Prescribing must come from — or in consultation with — a provider specialized in transgender youth care. Acceptable specialties include pediatric endocrinology, family medicine, internal medicine, and OB/GYN. That provider must have collaborated with a mental health provider for members under 18.

If your practice bills testosterone cypionate injections for adolescent patients and the prescriber isn't from one of these specialties, the claim is at risk. Talk to your billing consultant about how to document consultation arrangements.

Performance Enhancement

Aetna excludes performance enhancement categorically. Most plan documents include an explicit exclusion. For plans without that exclusion, Aetna still won't cover it — the policy states that performance enhancement of non-diseased individuals is not treatment of disease or injury. Don't bill J1071 or J1072 for this indication.

CPB 1014 does not specify prior authorization requirements. Verify plan-level prior auth requirements directly with Aetna's provider portal before initiating therapy to avoid retroactive denials.

---

Aetna Testosterone Cypionate Exclusions and Non-Covered Indications

Aetna considers all indications outside hypogonadism and gender dysphoria experimental, investigational, or unproven. That's a broad exclusion with real billing exposure.

The ICD-10 codes in the policy data tell an interesting story here. Codes like F52.0 (hypoactive sexual desire disorder), F52.22 (female sexual arousal disorder), N95.1 (menopausal and female climacteric states), Z78.0 (asymptomatic menopausal state), R41.81 (age-related cognitive decline), and Z85.46 (personal history of prostate cancer) appear in the policy's code set — but as context codes, not covered indications. These diagnoses show up in the literature as off-label uses for testosterone therapy. Aetna is not covering them here.

Heart failure codes (I50.1–I50.9) also appear in the code set. Based on the policy's comorbidity control language, this likely reflects documentation of comorbid conditions that affect eligibility — not a covered indication for testosterone therapy itself. That's an editorial read, not a designation Aetna assigns explicitly in CPB 1014.

The takeaway: diagnoses beyond hypogonadism and gender dysphoria will trigger denials. Don't pair J1071 or J1072 with these codes as primary diagnoses and expect coverage.

Oral, buccal, topical, and nasal androgen products are out of scope for CPB 1014. Those route-of-administration formulations fall under the pharmacy benefit. Don't bill them through the medical benefit under this policy.

---

Coverage Indications at a Glance

---

Aetna Testosterone Cypionate Billing Guidelines and Action Items 2025

These steps are specific to CPB 1014. Run through them before the effective date of December 20, 2025.

Copy Action Items

If you're unsure how this policy applies to your specific patient mix — particularly around adolescent gender dysphoria cases or off-label diagnoses — loop in your compliance officer before the effective date.

---

CPT, HCPCS, and ICD-10 Codes for Testosterone Cypionate Under CPB 1014

HCPCS Codes — Covered When Selection Criteria Are Met

Code	Type	Description Copy
J1071	HCPCS	Injection, testosterone cypionate, 1 mg
J1072	HCPCS	Injection, testosterone cypionate (Azmiro), 1 mg

CPT Codes — Related to CPB 1014

These codes are listed in CPB 1014 as related to the policy. The policy data does not assign a coverage status to these codes.

ICD-10-CM Diagnosis Codes Listed in CPB 1014

The policy data lists these codes as related to CPB 1014. Covered indications are defined by the medical necessity criteria above — not by code listing alone. Editorial notes below reflect interpretation of how these codes function in the policy context, not designations assigned by Aetna in the source data.

---